Evidence map›Paper›PMID 21370254›Full record

ArticleGenetic epidemiology2011

Efficient study design for next generation sequencing.

Joshua Sampson, Kevin Jacobs, Meredith Yeager, Stephen Chanock, Nilanjan Chatterjee

Abstract read
In one paragraph

Article in Genetic epidemiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Bioinformatics Strategies, Challenges, and Opportunities for Next Generation Sequencing-Based HLA Genotyping.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joshua SampsonBiostatistics Branch, DCEG, National Cancer Institute, Rockville, MD 20852, USA. joshua.sampson@nih.gov
Kevin Jacobs
Meredith Yeager
Stephen Chanock
Nilanjan Chatterjee

Funding

Methods for Epidemiology StudiesZIACP010181 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2009 to 2025
$34.8M
Methods for Epidemiology StudiesZ01CP010181 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI CHATTERJEE, NILANJAN · 2003 to 2008
$4.8M
Intramural NIH HHS Z01 CP010181
6 · The paper itself

Abstract

Next Generation Sequencing represents a powerful tool for detecting genetic variation associated with human disease. Because of the high cost of this technology, it is critical that we develop efficient study designs that consider the trade-off between the number of subjects (n) and the coverage depth (µ). How we divide our resources between the two can greatly impact study success, particularly in pilot studies. We propose a strategy for selecting the optimal combination of n and µ for studies aimed at detecting rare variants and for studies aimed at detecting associations between rare or uncommon variants and disease. For detecting rare variants, we find the optimal coverage depth to be between 2 and 8 reads when using the likelihood ratio test. For association studies, we find the strategy of sequencing all available subjects to be preferable. In deriving these combinations, we provide a detailed analysis describing the distribution of depth across a genome and the depth needed to identify a minor allele in an individual. The optimal coverage depth depends on the aims of the study, and the chosen depth can have a large impact on study success.

Indexed as

High-Throughput Nucleotide SequencingResearch DesignSequence Analysis, DNAAllelesGenetic Predisposition to DiseaseGenome, HumanGenome-Wide Association StudyHumansPolymorphism, Single NucleotideSample Size

Identifiers

PMID21370254
PMCPMC3291790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.